These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy. Chandorkar AG; Burte NP; Gade RK; Bulakh PM Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381 [TBL] [Abstract][Full Text] [Related]
63. The chemotherapy of leprosy. Part 1. Ellard GA Int J Lepr Other Mycobact Dis; 1990 Dec; 58(4):704-16. PubMed ID: 2280120 [No Abstract] [Full Text] [Related]
64. Recent advances in the treatment of leprosy. Ishii N Dermatol Online J; 2003 Mar; 9(2):5. PubMed ID: 12639458 [TBL] [Abstract][Full Text] [Related]
65. Evaluation of treatment of lepromatous leprosy patients in the Netherlands. Faber WR; Leiker DL Dermatologica; 1979; 158(1):46-54. PubMed ID: 367843 [TBL] [Abstract][Full Text] [Related]
66. Implementation of tests for monitoring drug compliance of leprosy out-patients under multi-drug therapy. Balakrishnan S; Kumar A; Rao BR; Patro TP Indian J Lepr; 1986; 58(4):555-9. PubMed ID: 3572097 [TBL] [Abstract][Full Text] [Related]
67. Advances in the diagnosis and treatment of leprosy. Katoch VM Expert Rev Mol Med; 2002 Jul; 4(15):1-14. PubMed ID: 14585155 [TBL] [Abstract][Full Text] [Related]
68. Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy. Goulart IM; Reis AC; De Rezende TM; Borges AS; Ferreira MS; Nishioka SA Lepr Rev; 2005 Jun; 76(2):167-9. PubMed ID: 16038251 [No Abstract] [Full Text] [Related]
69. Current status of leprosy: epidemiology, basic science and clinical perspectives. Suzuki K; Akama T; Kawashima A; Yoshihara A; Yotsu RR; Ishii N J Dermatol; 2012 Feb; 39(2):121-9. PubMed ID: 21973237 [TBL] [Abstract][Full Text] [Related]
70. Generalized annular borderline tuberculoid leprosy and update in management of Hansen's disease. Young RJ; Gilson RT; Elston DM Cutis; 2000 Apr; 65(4):203-6. PubMed ID: 10795079 [TBL] [Abstract][Full Text] [Related]
71. Efficacy of WHO regimens in the management of leprosy patients with G6PD deficiency. Mysore V; al-Suwaid AR Int J Lepr Other Mycobact Dis; 1999 Jun; 67(2):159-61. PubMed ID: 10472369 [No Abstract] [Full Text] [Related]
72. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae. Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663 [TBL] [Abstract][Full Text] [Related]
73. Analysis of bacteriological Index between fixed multidrug therapy and new WHO recommended alternative regimen with ofloxacin, minocycline and clofazimine of rifampicin resistant cases from the hospitals of The Leprosy Mission, India. Lavania M; Darlong J; Singh I; Ahuja M; Turankar RP; Pathak VK; Kumar A; Nathan R; Sengupta U J Glob Antimicrob Resist; 2020 Dec; 23():275-277. PubMed ID: 33068781 [No Abstract] [Full Text] [Related]
74. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy. Bach MA; Wallach D; Flageul B; Hoffenbach A; Cottenot F Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):256-67. PubMed ID: 3522769 [TBL] [Abstract][Full Text] [Related]
75. Repurposing Drugs to Combat Drug Resistance in Leprosy: A Review of Opportunities. Sharma M; Singh P Comb Chem High Throughput Screen; 2022; 25(10):1578-1586. PubMed ID: 34620073 [TBL] [Abstract][Full Text] [Related]
76. Antileprosy drugs, pregnancy and fetal outcome. Bhargava P; Kuldeep CM; Mathur NK Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):457-8. PubMed ID: 9030117 [No Abstract] [Full Text] [Related]